• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Positive programming of the GC-IGF1 axis mediates adult osteoporosis susceptibility in male offspring rats induced by prenatal dexamethasone exposure
In conclusion, PDE-induced intrauterine hypoglucocorticoid exposure could positively program IGF1 expression in bone tissue through the GRα/miR-130a-5p/HDAC4 pathways, thus mediating osteogenic dysdifferentiation and adult osteoporosis susceptibility in male offspring rats.PMID:36174767 | DOI:10.1016/j.bcp.2022.115264
Source: Biochemical Pharmacology - September 29, 2022 Category: Drugs & Pharmacology Authors: Yangfan Shangguan Xufeng Li Jun Qin Yinxian Wen Hui Wang Liaobin Chen Source Type: research

Effect of lncRNA AK023948 on rats with postmenopausal osteoporosis via PI3K/AKT signaling pathway.
CONCLUSIONS: LncRNA AK0 can regulate the phosphorylation level of AKT in osteoblasts of rats with estrogen deficiency-related osteoporosis through the PI3K/AKT signaling pathway, thus regulating the proliferation of osteoblasts. It is speculated that lncRNA AK0 may be an important factor in regulating the PI3K/AKT signaling pathway. PMID: 32196569 [PubMed - as supplied by publisher]
Source: European Review for Medical and Pharmacological Sciences - March 21, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

LncRNA UCA1 affects osteoblast proliferation and differentiation by regulating BMP-2 expression.
CONCLUSIONS: Inhibiting lncRNA UCA1 can promote the proliferation and differentiation of osteoblasts by activating the BMP-2/(Smad1/5/8) signaling pathway in osteoblasts. Therefore, UCA1 is expected to be a new therapeutic target for OST. PMID: 31486475 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - September 7, 2019 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

RNA-based Therapy for Osteogenesis
Publication date: Available online 5 August 2019Source: International Journal of PharmaceuticsAuthor(s): Pinpin Wang, Federico Perche, Delphine Logeart-Avramoglou, Chantal PichonAbstractNucleic acid-based therapy has shown great promise in accelerating bone regeneration as well as other diseases. Nucleic acids used in gene therapy mainly are either plasmid DNA (pDNA) or RNAs. Although pDNA therapy has been extensively studied for decades with encouraging preclinical and clinical results, side effects, and low efficiency associated with nuclear trafficking are hard to bypass. Unlike pDNA, RNAs (mRNA, siRNA, miRNA) exert the...
Source: International Journal of Pharmaceutics - August 6, 2019 Category: Drugs & Pharmacology Source Type: research

LncRNA MALAT1 inhibits osteogenic differentiation of mesenchymal stem cells in osteoporosis rats through MAPK signaling pathway.
CONCLUSIONS: LncRNA MALAT1 was lowly expressed in OP rats. Moreover, it inhibited osteogenic differentiation of BMSCs by enhancing the activation of the MAPK signaling pathway, thereby promoting OP progression. PMID: 31210287 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - June 20, 2019 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Plant-Derived Alkaloids: The Promising Disease-Modifying Agents for Inflammatory Bowel Disease
Conclusion This paper summarizes the current findings regarding the anti-colitis activity of plant-derived alkaloids and shows how these alkaloids exhibit significant and beneficial effects in alleviating colonic inflammation. These natural alkaloids are not only promising agents for IBD treatment but are also components for developing new wonder drugs. However, the underlying molecular mechanisms or toxicological evaluation of most plant-derived alkaloids still require much scientific research, and their actual efficacies for IBD patients have not been verified well in field research. Thus, further clinical trials to elu...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Activation of TGR5 promotes osteoblastic cell differentiation and mineralization
Publication date: December 2018Source: Biomedicine & Pharmacotherapy, Volume 108Author(s): Qingfeng Wang, Guoqiang Wang, Bin Wang, Huilin YangAbstractImpairment of normal osteoblast differentiation has been associated with bone loss-related disorders, such as osteoporosis. Takeda G-protein coupled receptor 5 (TGR5) has been identified as an important modulator of bile acid and energy homeostasis. Little information regarding the effects of TGR5 on osteoblastic bone formation and matrix mineralization has been reported before. In the current study, we found that TGR5 was expressed in osteoblast-like cell line MC3T3-E1 cells...
Source: Biomedicine and Pharmacotherapy - October 16, 2018 Category: Drugs & Pharmacology Source Type: research

CRNDE impacts the proliferation of osteoclast by estrogen deficiency in postmenopausal osteoporosis.
CONCLUSIONS: We found that lncRNA CRNDE was closely related to the postmenopausal osteoporosis with estrogen deficiency. CRNDE may be involved in the development and progression of postmenopausal osteoporosis in the absence of estrogen and become a potential target for treating. PMID: 30280760 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - October 5, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Immunization with Na+/K+ ATPase DR peptide prevents bone loss in an ovariectomized rat osteoporosis model.
Abstract Osteoporosis is characterized by decreased bone strength and microarchitectural deterioration of bone tissue leading to an increase in bone fracture. Here we report a new agent named DR peptide, a conserved sequence of Na+/K+ ATPase (NKA), can be used to prevent osteoporosis. Our results showed that immunization with DR peptide conjunct with Keyhole limpet hemocyanin (DR-KLH) significantly strengthened trabecular bone and improved bone mineral density of femur and the 5th lumbar in the ovariectomized (OVX) rats when compared with those in OVX rats immunized with KLH alone. To study the underlying mechanis...
Source: Biochemical Pharmacology - August 19, 2018 Category: Drugs & Pharmacology Authors: Xiong S, Yang X, Yan X, Hua F, Zhu M, Guo L, Wu Z, Bian JS Tags: Biochem Pharmacol Source Type: research

Icariin promotes proliferation and osteogenic differentiation of rat adipose-derived stem cells by activating the RhoA-TAZ signaling pathway
Publication date: April 2017 Source:Biomedicine & Pharmacotherapy, Volume 88 Author(s): Yaping Ye, Xingzhi Jing, Na Li, Yingxing Wu, Bingbing Li, Tao Xu Icariin, the main active flavonoid glucoside isolated from Herba epimedii, has been demonstrated to be a potential alternative therapy to prevent postmenopausal osteoporosis. Icariin has also been shown to regulate the proliferation and osteogenic differentiation of rat bone marrow stromal cells (rBMSCs). However, the detailed molecular mechanism of icariin has remained largely unknown. Besides, no investigation has focused on the relevance of icariin in the regul...
Source: Biomedicine and Pharmacotherapy - January 21, 2017 Category: Drugs & Pharmacology Source Type: research

Icariin promotes proliferation and osteogenic differentiation of rat adipose-derived stem cells by activating the RhoA-TAZ signaling pathway.
Abstract Icariin, the main active flavonoid glucoside isolated from Herba epimedii, has been demonstrated to be a potential alternative therapy to prevent postmenopausal osteoporosis. Icariin has also been shown to regulate the proliferation and osteogenic differentiation of rat bone marrow stromal cells (rBMSCs). However, the detailed molecular mechanism of icariin has remained largely unknown. Besides, no investigation has focused on the relevance of icariin in the regulation of rat adipose-derived stem cells (rASCs) proliferation and osteogenic differentiation. In the present study, we detected that icariin pro...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 21, 2017 Category: Drugs & Pharmacology Authors: Ye Y, Jing X, Li N, Wu Y, Li B, Xu T Tags: Biomed Pharmacother Source Type: research

Methionine Downregulates TLR‐4/MyD88/NF‐κB Signaling in Osteoclasts Precursors to Reduce Bone Loss during Osteoporosis
Conclusions and ImplicationsMethionine prevents OVX induced bone loss by disrupting functional osteoclast development via TLR‐4/MyD88/NF‐κB signaling pathway. Methionine supplementation could be beneficial for treatment against post‐menopausal osteoporosis.
Source: British Journal of Pharmacology - September 30, 2013 Category: Drugs & Pharmacology Authors: V. Vijayan, M. Khandelwal, K. Manglani, S. Gupta, A. Surolia Tags: Research Paper Source Type: research